Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April 2014
March 28 2014 - 3:24PM
Galapagos NV (Euronext: GLPG) has the
honor to invite the Shareholders, Warrant Holders, Directors and
Statutory Auditor of the Company to the Annual and Extraordinary
General Shareholders' Meeting that will be held on Tuesday 29 April
2014 at 2:00 p.m. (CET) at the registered office of the
Company.
In order to be admitted to the Shareholders'
Meeting, the holders of securities issued by the Company must
comply with article 536 of the Belgian Companies Code and
article 29 of the articles of association of the Company, and
fulfill the formalities and make the notifications described in the
convening notice.
The convening notice and other relevant documents can be found
at
http://www.glpg.com/index.php/companyoverview/shareholder-information/shareholder-meetings/
About Galapagos Galapagos
(Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising five Phase 2
studies (two led by GSK), one Phase 1 study, six pre-clinical, and
20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will
be responsible for further development and commercialization of
GLPG0634 after Phase 2B. GLPG0634 is an orally-available,
selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in
Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos has another selective JAK1 inhibitor in
Phase 2 in ulcerative colitis and psoriasis, GSK2586184 (formerly
GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0974
is the first inhibitor of FFA2 to be evaluated clinically for the
treatment of IBD; this program is currently in a Proof-of-Concept
Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and has completed Phase 1. AbbVie
and Galapagos signed an agreement in CF whereby they work
collaboratively to develop and commercialize oral drugs that
address two mutations in the CFTR gene, the G551D and F508del
mutation. Potentiator GLPG1837 is at the pre-clinical
candidate stage. Galapagos has 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Elizabeth Goodwin, Head of Corporate
Communications & Investor Relations Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking
statements, including, without limitation, statements containing
the words "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," and
"continues," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
Invitation to the Shareholders' Meeting
http://hugin.info/133350/R/1772463/603873.pdf
HUG#1772463
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024